PMID- 1447905 OWN - NLM STAT- MEDLINE DCOM- 19921229 LR - 20170214 IS - 0023-6772 (Print) IS - 0023-6772 (Linking) VI - 26 IP - 4 DP - 1992 Oct TI - Subcutaneous administration of HMG-CoA reductase inhibitors in hyperlipidaemic and normal rats. PG - 269-80 AB - Recent reports demonstrate a hypocholesterolaemic effect of daily subcutaneous injections of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors in different rat models of hyperlipidaemia. However, this effect is not seen after oral administration of HMG-CoA reductase inhibitors in rats. We found that oral administration of the HMG-CoA reductase inhibitor Simvastatin also had no effect on plasma cholesterol in severely hyperlipidaemic Nagase analbuminaemic rats (NAR). Simvastatin (an apolar compound dissolved in propylene glycol) was infused continuously for 28 days into the subcutis of control Sprague-Dawley rats (SDR) and NAR using an implanted osmotic pump. All doses which were effective in reducing cholesterol in the NAR (reductions up to approximately 60%), reduced apolipoprotein AI but not apolipoprotein B and caused a severe inflammatory reaction in the dermis. Similar toxicity was observed in the SDR. Subcutaneous administration of the vehicle (propylene glycol) did not cause this reaction and did not affect plasma lipids. Administration of Lovastatin in osmotic pumps resulted in a similar inflammatory reaction. Incorporation of Simvastatin into liposomes did not diminish the toxic effect. On the other hand, infusion of Pravastatin (a polar HMG-CoA reductase inhibitor dissolved in isotonic saline) caused no changes in the dermis and had no effect on plasma lipids in NAR or SDR. Liver microsomes prepared from the Pravastatin-treated rats demonstrated a 3- to 4-fold increase in HMG-CoA reductase activity as compared to untreated rats, confirming uptake of the drug. We conclude that continuous subcutaneous administration of the HMG-CoA reductase inhibitors Simvastatin, Lovastatin and Pravastatin for 28 days may not reduce plasma cholesterol in rats by a mechanism which is related to inhibition of HMG-CoA reductase activity in the liver. The decrease of plasma cholesterol effected by subcutaneous infusion of Simvastatin or Lovastatin in NAR coincides with, and may be related to inflammatory changes caused by administering these compounds into the dermis. FAU - Joles, J AU - Joles J AD - Department of Nephrology, Medical Faculty, University of Utrecht, The Netherlands. FAU - Willekes-Koolschijn, N AU - Willekes-Koolschijn N FAU - Koomans, H AU - Koomans H FAU - Van Tol, A AU - Van Tol A FAU - Geelhoed-Mieras, T AU - Geelhoed-Mieras T FAU - Crommelin, D AU - Crommelin D FAU - Van Bloois, L AU - Van Bloois L FAU - Krajnc-Franken, M AU - Krajnc-Franken M FAU - Cohen, L AU - Cohen L FAU - Griffioen, M AU - Griffioen M AU - et al. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't PL - England TA - Lab Anim JT - Laboratory animals JID - 0112725 RN - 0 (Anticholesteremic Agents) RN - 0 (Hydroxymethylglutaryl-CoA Reductase Inhibitors) RN - 9LHU78OQFD (Lovastatin) RN - AGG2FN16EV (Simvastatin) RN - KXO2KT9N0G (Pravastatin) SB - IM MH - Administration, Oral MH - Animals MH - Anticholesteremic Agents/*administration & dosage/toxicity MH - Female MH - *Hydroxymethylglutaryl-CoA Reductase Inhibitors MH - Hypercholesterolemia/blood/drug therapy/pathology MH - Infusion Pumps, Implantable MH - Injections, Subcutaneous MH - Lovastatin/*administration & dosage/*analogs & derivatives/toxicity MH - Pravastatin/*administration & dosage/toxicity MH - Rats MH - Rats, Mutant Strains MH - Rats, Sprague-Dawley MH - Simvastatin EDAT- 1992/10/01 00:00 MHDA- 1992/10/01 00:01 CRDT- 1992/10/01 00:00 PHST- 1992/10/01 00:00 [pubmed] PHST- 1992/10/01 00:01 [medline] PHST- 1992/10/01 00:00 [entrez] AID - 10.1258/002367792780745689 [doi] PST - ppublish SO - Lab Anim. 1992 Oct;26(4):269-80. doi: 10.1258/002367792780745689.